“The construction of the R&D facility is intended to strengthen competitiveness,” the company said.
Samsung Bioepis, which was established in 2012 in a joint venture between Samsung Biologics and Biogen, mostly manufactures biosimilars.
The market for biosimilars has grown in recent years as such drugs are available to customers at a discount. Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire.
By Ram Garikipati and newswires (firstname.lastname@example.org)